Ginkgo Bioworks Holdings Inc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
DNA$12.01-2.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash flows from operating activities: | |||
| Net loss | $(547,029) | $(892,869) | $(2,106,372) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 63,020 | 70,507 | 42,552 |
| Stock-based compensation | 112,344 | 229,884 | 1,930,641 |
| Goodwill impairment | 47,858 | — | — |
| Restructuring related impairment charges | 4,823 | — | — |
| Non-cash customer consideration | (1,117) | (1,373) | (34,263) |
| Loss on equity method investments | — | 2,635 | 43,761 |
| Loss on investments | 28,827 | 54,827 | 53,335 |
| Change in fair value of notes receivable | 2,014 | 2,416 | (3,757) |
| Change in fair value of warrant liabilities | (5,701) | (5,168) | (124,970) |
| Change in fair value of contingent consideration liability | 3,214 | 9,168 | (1,262) |
| Loss (gain) on deconsolidation of subsidiaries | 7,013 | 42,502 | (31,889) |
| Impairment of long-lived assets | 5,796 | 121,404 | — |
| Deferred income tax benefit | (936) | (801) | (14,609) |
| Loss on disposal of equipment | 844 | 842 | 3,091 |
| Non-cash lease expense | 28,095 | 28,313 | 19,082 |
| Non-cash in-process research and development | 19,796 | 9,182 | 1,162 |
| Non-cash severance and retention bonus expense associated with an acquisition | — | — | 6,152 |
| Other non-cash activity | 1,224 | 3,194 | 2,154 |
| Changes in operating assets and liabilities: | |||
| Accounts receivable ($156, $816 and $3,040 from related parties) | (4,725) | 50,068 | 55,024 |
| Prepaid expenses and other current assets | 10,085 | 10,473 | (8,523) |
| Operating lease right-of-use assets | 23,463 | 9,275 | 13,233 |
| Other non-current assets | (1,394) | 2,570 | 921 |
| Accounts payable | 4,771 | (1,183) | (10,844) |
| Accrued expenses and other current liabilities | (40,438) | 16,899 | (39,639) |
| Deferred revenue, current and non-current ($(51,422), $(17,018) and $(19,324) from related parties) | (68,645) | (35,917) | (36,417) |
| Operating lease liabilities, current and non-current | (14,881) | (22,800) | (10,792) |
| Other non-current liabilities | 2,094 | 452 | 31 |
| Net cash used in operating activities | (319,585) | (295,500) | (252,198) |
| Cash flows from investing activities: | |||
| Purchases of property and equipment | (62,541) | (40,801) | (52,271) |
| Deconsolidation of subsidiaries - cash | — | (42,980) | (55,721) |
| Business acquisitions, net of cash acquired | (5,400) | — | 82,367 |
| Asset acquisitions, net of cash acquired | — | — | (7,639) |
| Purchases of notes receivable (2022: $10,000 from related party) | — | (350) | (40,000) |
| Proceeds from notes receivable | — | — | 10,000 |
| Purchase of investment in equity securities | — | — | (3,691) |
| Proceeds from sales of marketable securities | 4,519 | — | — |
| Proceeds from sale of equipment | 648 | 4,428 | — |
| Other | 538 | (990) | (439) |
| Net cash used in investing activities | (62,236) | (80,693) | (67,394) |
| Cash flows from financing activities: | |||
Consolidated Statements of Cash Flows
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Proceeds from exercise of stock options | 84 | 93 | 240 |
| Taxes paid related to net share settlement of equity awards | — | (23) | (981) |
| Principal payments on finance leases | (897) | (1,295) | (1,237) |
| Proceeds from public offering, net of issuance costs | — | — | 99,303 |
| Contingent consideration payment | (922) | (1,411) | (521) |
| Payment of equity issuance costs and other | (4) | (580) | (1,467) |
| Net cash (used in) provided by financing activities | (1,739) | (3,216) | 95,337 |
| Effect of foreign exchange rates on cash and cash equivalents | (281) | (588) | 908 |
| Net decrease in cash, cash equivalents and restricted cash | (383,841) | (379,997) | (223,347) |
| Cash and cash equivalents, beginning of year | 944,073 | 1,315,792 | 1,550,004 |
| Restricted cash, beginning of year | 45,511 | 53,789 | 42,924 |
| Cash, cash equivalents and restricted cash, beginning of year | 989,584 | 1,369,581 | 1,592,928 |
| Cash and cash equivalents, end of year | 561,572 | 944,073 | 1,315,792 |
| Restricted cash, end of year | 44,171 | 45,511 | 53,789 |
| Cash, cash equivalents and restricted cash, end of year | $605,743 | $989,584 | $1,369,581 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.